The pharmacological targeting of MIF signaling pathways and receptors using small synthetic molecules (nanobodies), antibodies, or receptor-targeted peptides, is of particular interest in cancer treatment, as it counteracts the pro-proliferative effects of MIF and D-DT. The gene discussed is MIF; the disease is cancer.